Exploration of association of 1,25-OH2D3 with augmentation index, a composite measure of arterial stiffness

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 6, 2008, Pages 1800-1806

  Andrade, Jason ^a   Er, Lee ^a   Ignaszewski, Andrew ^a   Levin, Adeera ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIFEDIOL; CALCITRIOL; CALCIUM; GELATINASE A; GELATINASE B; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MMP2 PROTEIN, HUMAN; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG;

AGED; AORTA; ARTICLE; BLOOD; CANADA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; ELASTICITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RISK ASSESSMENT;

AGED; AORTA; BIOLOGICAL MARKERS; BRITISH COLUMBIA; C-REACTIVE PROTEIN; CALCIFEDIOL; CALCITRIOL; CALCIUM; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ELASTICITY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INTERLEUKIN-6; KIDNEY DISEASES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; RISK ASSESSMENT;

EID: 58149354343     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00900208     Document Type: Article

References (28)

1. Kampus P, Kals J, Ristimae T, Fischer K, Zilmer M, Teesalu R: High-sensitivity C-reactive protein affects central haemodynamics and augmentation index in apparently healthy persons. J Hypertens 22: 1133-1139, 2004
2. Oparil S, Izzo JL Jr: Pulsology rediscovered: Commentary on the Conduit Artery Function Evaluation (CAFÉ) Study. Circulation 113: 1162-1163, 2006
3. Hansen TW, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113: 664-670, 2006
4. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 113: 1213-1225, 2006
5. Nürnberger J, Keflioglu-Scheiber A, Opazo Saez AM, Wenzel RR, Philipp T, Schäfers RF: Augmentation index is associated with cardiovascular risk. J Hypertens 20: 2407-2414, 2002
6. Pietri P, Vyssoulis G, Vlachopoulos C, Zervoudaki A, Gialernios T, Aznaouridis K, Stefanadis C: Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 24: 2231-2238, 2006
7. Kullo I, Seward J, Bailey K, Bielak L, Grossardt B, Sheedy IIP, Peyser P, Turner S. Am J Hypertens 18: 1123-1129, 2005
8. Yasmin, Wallace S, McEniery CM, Dakham Z, Pusalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB: Matrix metalloproteinase-9 (MMP-9), MMP-2 and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25: 372-378, 2005
9. Palmer M, Adami HO, Bergstrom R, Akerstrom G, Ljunghall S: Mortality after surgery for primary hyperparathyroidism: A follow-up of 441 patients operated on from 1956 to 1979. Surgery 102: 1-7, 1987
10. Lundgren E, Lind L, Palmer M, Jakobsson S, Ljunghall S, Rastad J: Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 130: 978-985, 2001
11. Hedbäck GM, Odén AS: Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. J Intern Med 251(6): 476-483, 2002
12. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol 16: 1788-1793, 2005
13. Langle F, Abela C, Koller-Strametz J, Mittelbock M, Bergler-Klein J, Stefenelli T, Woloszczuk W, Niederle B: Primary hyperparathyroidism and the heart: Cardiac abnormalities correlated to clinical and biochemical data. World J Surg 18(4): 619-624, 1994
14. Andersson P, Rydberg E, Willenheimer R: Primary hyperparathyroidism and heart disease - A review. Eur Heart J 25(20): 1776-1787, 2004
15. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ: Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 90(6): 3326-3330, 2005
16. Kiernan TJ, O'Flynn AM, McDermott JH, Kearney P: Primary hyperparathyroidism and the cardiovascular system. Int J Cardiol 113(3): E89-E92, 2006
17. Levin A, Li YC: Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 68: 1973-1981, 2005
18. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
19. Smulyan H, Siddiqui DS, Carlson RJ, London GM, Safar ME: Clinical utility of aortic pulses and pressures calculated from applanated radial-artery pulses. Hypertension 42: 150-155, 2003
20. Vlachopoulos C, Aznaouridis K, Dima I, Ioakeimidis N, Vasiliadou C, Zervoudaki A, Gialernios T, Stefanadis C: Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. Int J Cardiol 122: 232-238, 2007
21. Yasmin, Brown MJ: Similarities and differences between augmentation index and pulse wave velocity in the assessment of arterial stiffness. Q J Med 92: 595-600, 1999
22. Michos ED, Blumenthal RS: Vitamin D supplementation and cardiovascular disease risk. Circulation 115: 827-828, 2007
23. Tayebjee MH, Nadar SK, Blann AD, Beevers G, MacFadyen RJ, Lip GY: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension: Relationship to cardiovascular risk and treatment. Am J Hypertens 17(9): 764-769, 2004
24. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: Mechanisms for inflammatory damage in chronic disorders? Q J Med 95: 787-796, 2002
25. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647, 2002
26. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: e10-e17, 2000
27. Tonelli M, Sacks F, Pfeffer M, Gao Z Curhan G: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633, 2005
28. Mitchell GF, Conlin PR, Dunlap ME, Lacourciere Y, Arnold JMO, Ogilvie RI, Neutel J, Izzo JL, Pfeffer MA: Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension 51: 105-111, 2008